Updates are available Correction dated 2025-03-24
Click to view Correction: https://doi.org/10.1038/s41467-025-58288-2
-
Authors
Solovyov, Alexander
Behr, Julie M. https://orcid.org/0000-0001-8601-4902
Hoyos, David
Banks, Eric
Drong, Alexander W.
Thornlow, Bryan
Zhong, Jimmy Z.
Garcia-Rivera, Enrique
McKerrow, Wilson
Chu, Chong https://orcid.org/0000-0002-0796-2339
Arisdakessian, Cedric https://orcid.org/0000-0001-5255-0942
Zaller, Dennis M.
Kamihara, Junne https://orcid.org/0000-0002-2852-7387
Diao, Liyang
Fromer, Menachem https://orcid.org/0000-0003-3749-4342
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748, R01AI081848, U01CA228963)
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 12 February 2025
First Online: 28 February 2025
Change Date: 24 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-58288-2
Competing interests
: At the time of the work, J.M.B., B.T., A.W.D., J.Z.Z., E.G.R., W.M., C.C., C.A., L.D., D.M.Z., and M.F. were full-time employees of, and hold stock options of, ROME Therapeutics. B.D.G. is a scientific co-founder of, consults for, and holds stock options of ROME Therapeutics. B.D.G. received honoraria from Merck, Bristol Meyers Squibb (BMS), and Chugai Pharmaceuticals; research funding from BMS and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma, Shennon Biotechnologies, and Synteny.AI. A.S. has done consulting work for PMV Pharma and ROME Therapeutics; he holds stock options of ROME Therapeutics. E.B. is a full-time employee of The Broad Institute. J.K. spouse has received consulting fees from ROME Therapeutics, PanTher Therapeutics, Tekla Capital, abrdn, and Sonata Therapeutics; is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc.; is on the advisory board for ImproveBio, Inc.; has received honorariums from AstraZeneca, Moderna and Ikena Oncology; and receives research support from ACD-Biotechne, AVA LifeScience GmbH, Incyte Pharmaceuticals, and Sanofi. The remaining authors declare no competing interests.
